$25.00 Plus stock for less than $10.00
Still a great buy.
My favorite part of todays news:
Whaijen Soo, MD, PhD, senior vice president, Medical Research, Biogen Idec. "Given the high unmet medical need in MS and the therapeutic benefit we have seen with TYSABRI, we are encouraged by these safety findings."